Eli Lilly and Company Limited v Apotex Pty Ltd

Link copied
Case Copied 71 min read

FEDERAL COURT OF AUSTRALIA

Eli Lilly and Company Limited v Apotex Pty Ltd [2013] FCA 214

Citation: Eli Lilly and Company Limited v Apotex Pty Ltd [2013] FCA 214
Parties: ELI LILLY AND COMPANY LIMITED and ELI LILLY AUSTRALIA PTY LTD (ABN 39 000 233 992) v APOTEX PTY LTD (ABN 52 096 916 148)
File number: VID 876 of 2009
Judge: MIDDLETON J
Date of judgment: 15 March 2013
Catchwords: INTELLECTUAL PROPERTY – Patents – Construction of claims – Infringement of claims – Applicable principles – Skilled addressee – Revocation for invalidity – Novelty – Generic chemical disclosure – Prior art and common general knowledge – Selection patents – Inventive step – Secondary considerations – Commercial success – Sufficiency – Fair basis – Lack of clarity – Manner of new manufacture
Legislation:

Patents Act 1903-1950 (Cth)
Patents Act 1949 (UK)
Patents Act 1952 (Cth)

Patents Act 1952-1955 (Cth)
Patents Act 1990 (Cth)

Cases cited:

Advanced Building Systems Pty Limited v Ramset Fasteners (Aust) Pty Limited (1998) 194 CLR 171
Aktiebolaget Hässle v Alphapharm Pty Limited (2002) 212 CLR 411
Aktiebolaget Hässle v Alphapharm Pty Ltd (1999) 44 IPR 593; [1999] FCA 628
Alphapharm Pty Ltd v H Lundbeck A/S (2008) 76 IPR 618; [2008] FCA 559
American Home Products Corporation [1994] APO 58 (28 September 1994)
Apotex Pty Ltd (formerly GenRx Pty Ltd) v Sanofi-Aventis (2008) 78 IPR 485; [2008] FCA 1194
Apotex Pty Ltd v AstraZeneca AB (No 4) [2013] FCA 162
Apotex Pty Ltd v Sanofi-Aventis (2009) 82 IPR 416; [2009] FCAFC 134
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 2) (2012) 204 FCR 494
Australian Mud Company Pty Ltd v Coretell Pty Ltd (2011) 93 IPR 188; [2011] FCAFC 121
Beecham Group Ltd v Bristol Laboratories International SA (1978) RPC 521
Bristol-Myers Co v L’Oreal (1988) 12 IPR 275
Bristol-Myers Co v L’Oreal (1988) 12 IPR 275
Bristol-Myers Co v L’Oreal (1989) 16 IPR 652
Bristol-Myers Squibb Co v F H Faulding & Co Limited (2000) 97 FCR 524
Britax Childcare Pty Ltd v Infa-Secure Pty Ltd (2012) 290 ALR 47
British Acoustic Films Ltd v Nettlefold Productions (1936) 53 RPC 221
British Thomson-Houston Co Ltd v Corona Lamp Works Ltd (1922) 39 RPC 49
Ccom Pty Ltd v Jiejing Pty Ltd (1994) 51 FCR 260
Clay v ICI Australia Operations Pty Ltd (1984) 3 IPR 439
Commissioner of Patents v Ethyl Corporation (1969) 120 CLR 594
Commissioner of Patents v Microcell Limited (1959) 102 CLR 232
Commissioner of Patents v The Wellcome Foundation Limited (1983) 2 IPR 156
Commonwealth Industrial Gases Ltd v MWA Holdings Pty Ltd (1970) 180 CLR 160
Conor Medsystems Inc v Angiotech Pharmaceuticals Inc [2008] 4 All ER 621
Conor Medsystems Inc v University of British Columbia (2005) 223 ALR 74
Décor Corporation Pty Ltd v Dart Industries Inc (1988) 13 IPR 385
Dr Reddy’s Laboratories (UK) Ltd v Eli Lilly and Co Ltd [2010] RPC 9
Dura-Post (Aust) Pty Ltd v Delnorth Pty…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Eli Lilly and Company Limited v Apotex Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] FCA 214
Decision Date

CaseChat Overview and Summary

Eli Lilly and Company Limited took action against Apotex Pty Ltd in the Federal Court of Australia, seeking declarations and injunctions regarding the validity and infringement of Australian Patent No. 683949. The patent, granted on 13 January 1994, claimed olanzapine, a compound used in the treatment of psychotic disorders. The dispute centred on the patent's validity, with Apotex alleging it was invalid due to lack of novelty, inventive step, and sufficiency of description. Eli Lilly, on the other hand, asserted the patent's validity and accused Apotex of infringement. The court had to determine whether the patent met the statutory requirements for novelty, inventive step, and sufficiency of description, as well as whether Apotex had infringed the patent.

The court first examined the patent's novelty, considering whether olanzapine was disclosed in the prior art, specifically the genus patents. Eli Lilly argued that olanzapine was not disclosed in the prior art, while Apotex contended that it was. The court found that olanzapine was not disclosed in the prior art and thus the patent was novel. Regarding inventive step, the court assessed whether olanzapine, as claimed, involved an inventive step over the prior art. The court held that olanzapine did indeed involve an inventive step because it possessed advantages over prior art compounds, such as fewer side effects and greater efficacy. On the issue of sufficiency of description, the court determined whether the patent sufficiently described the invention to enable a person skilled in the art to replicate it. The court concluded that the patent provided a full and enabling description of olanzapine and its advantages.

In summary, the court found that the patent was valid and that Apotex had infringed it. The court granted Eli Lilly the declarations and injunctions it sought, affirming the patent's validity and prohibiting Apotex from manufacturing, using, or selling olanzapine without Eli Lilly's consent.

Background

Background to the litigation

As Lockhart J said in NV Philips Gloeilampenfabrieken v Mirabella International Pty Limited (1993) 44 FCR 239 at 253-254 in relation to s 233(4) of the 1990 Act (which is in language to the same effect as s 234(5) of the Act): In my opinion the evident intent of s 233(4) is to ensure that the grounds of revocation under the 1990 Act (which, though in some cases are expressed in different terms, are essentially the same as the grounds previously available under s 100 of the 1952 Act) apply as the grounds for revocation of a 1952 Act patent; but with this important qualification, namely, that the elements of each ground of revocation under the 1990 Act apply only to the extent that they replicate in substance the elements that previously constituted a ground of revocation under the 1952 Act. Hence, if a ground of revocation under the 1990 Act omits an element which was a necessary part of a ground under the 1952 Act, the patentee has the benefit of it. On the other hand, if a ground under the 1990 Act contains an element not previously present under the 1952 Act, it cannot apply in aid of revocation of the 1952 Act patent. In short, a 1952 Act patentee is not to be worse off than he would have been if the 1952 Act had continued to operate, but he may be better off if the 1990 Act treats a former element of a ground of revocation as being no longer necessary.BACKGROUND Australian Patent No. 643267 and Related Patents On 26 November 1974, Lilly Industries Ltd filed GB provisional application number 51240. This provisional application led to a family of patents, including AU 506340 (the 340 Patent) and GB 1 533 235 (the 235 Patent). Both the 340 Patent and the 235 Patent (the genus patents) claimed a class of compounds that included olanzapine, although it is not mentioned specifically. The genus patents are effectively identical. The complete specifications for the 340 Patent and the 235 Patent were filed on 21 November 1975 and 24 November 1975 respectively. By s 22 of the Patents Act 1949 (UK) and s 68 of the 1952 Act, the term of each of the genus patents was 16 years from the date of filing. The genus patents claim a vast number of compounds. The named inventors of the Patent and the genus patents included Dr Jiban Kumar Chakrabarti and Dr David Edward Tupper. During the 1980s, Dr Chakrabarti, Dr Tupper and others published a series of papers relating to their work on antipsychotic compounds, including compounds covered by the genus patents. Eli Lilly conducted clinical trials from 1986 onwards. Eli Lilly made its product commitment in 1990. The application for the Patent was filed on 22 April 1991. The genus patents were published in 1977 (AU) and 1978 (UK). The Patent was published on 7 November 1991. The term of the Patent was extended to 5 March 2012. It seems that the patentee has effectively had continuing patent protection for olanzapine from 1977 until the expiry of the Patent. There was some suggestion made by counsel for Apotex of Eli Lilly “evergreening”, namely, being able to in effect re-monopolise olanzapine in the 1990s via the Patent, having initially obtained patent protection in the 1970s with the grant of the 235 Patent. Of course, this observation cannot impact upon the principles to be applied in this proceeding. The outcome must be the same as if the 235 Patent was claimed and owned by a third party unconnected to Eli Lilly.

Decision

Reasons for decision

The specification reveals the new qualities of the compound of the invention and positively asserts that there is an invention. On the basis of the specification itself, olanzapine is disclosed as a new compound with advantages over earlier compounds, as discussed in these reasons. On this aspect of the attack, the Court may not “go behind” these statements, ie rely on extrinsic evidence: see Apotex v Sanofi-Aventis (2009) 82 IPR 416 at 449 to 451 (per Bennett and Middleton JJ); Pilja v Rapidjoint (2009) 80 IPR 648 at 655 [41]; Ranbaxy Australia Pty Ltd v Warner-Lambert Co LLC (No 2) (2006) 71 IPR 46 at 103 [206]. This is sufficient for there to be no so-called ‘threshold’ problem in the Patent, as alleged by Apotex.Conclusion – Manner of Manufacture Even if the ground of “manner of new manufacture” was available as sought to be relied upon by Apotex, I am satisfied that the Patent on its face describes and claims a “manner of new manufacture”.SECTION 40 REQUIREMENTS I turn now to sufficiency of description.Sufficiency Apotex alleges that the complete specification of the Patent lacks sufficiency of full description, on the basis that it does not adequately describe the advantages of olanzapine over all other compounds within the genus of compounds described in the 340 Patent. Apotex alleges that the complete specification does not describe the invention fully, in that “being a selection from the genus of compounds”, the specification “does not disclose, explain or demonstrate the advantages claimed for the compound named in claims 1 to 4 and 7 over all other compounds within that genus”. I do not consider that special principles of sufficiency apply to a patent which is determined to satisfy the principles of selection for the purposes of novelty. In relation to the issue of novelty, a patent either satisfies the criteria for assessing novelty, or it does not. As indicated by the High Court in Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 217 CLR 274 (Lockwood No 1) at 290, 291 [43], [46] and 301 [70], the requirement of sufficiency is a separate inquiry which must not be conflated with other grounds of invalidity. By s 138(3)(f) of the 1990 Act, and by s 100(1)(c) of the 1952 Act, a patent may be revoked on the ground that it does not comply with the requirements of s 40. Section 40(2)(a) of the 1990 Act and s 40(1)(a) of the 1952 Act provide that a complete specification must describe the invention “fully”. The applicable principles are stated in Blanco White QC, Patents for Inventions, 5th ed (1983) at [4-502] as follows (citations omitted):To be proper and sufficient, the complete specification as a whole (that is, read together with the claims, and in the light of the drawings, if any) must in the first place contain such instructions as will enable all those to whom the specification is addressed to produce something within each claim “by following the directions of the specification, without any new inventions or additions of their own” and without “prolonged study of matters which present some initial difficulty.”

Ratio Decidendi

Legal Principle Established

From these data, the Patent concludes at p 14: This profile of activity in in vitro receptor binding assays, like that observed in the behavioural tests, would indicate that the compound is effective in the treatment of psychotic conditions but is less likely to induce extra pyramidal side-effects. Dosage and Administration The Patent teaches the dosage range that is effective to treat different conditions, including mild anxiety and psychotic disorders in adult humans. The Patent also discusses methods of administration of pharmaceutical compositions containing olanzapine, including suitable carriers for olanzapine and formulations thereof (at pp 14-16). Examples The invention is then illustrated by examples. Pages 17 to 23 of the Patent give details of seven examples. The first two examples describe two different ways to synthesise olanzapine. The remaining five examples relate to pharmaceutical formulations containing olanzapine. The Invention Claimed The specification ends in seven claims.(a)Claim 1 is directed to a single compound (namely, 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine) or its acid addition salts.(b)Claim 2 is limited to the single compound (2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine) which is the subject of claim 1.(c)Claims 3 and 4 are directed to pharmaceutical compositions which include the compound of claim 1 or its acid addition salts with a diluent or carrier.(d)Claim 5 is directed to a process for producing the compound of claim 1.(e)Claim 6 is directed to an intermediate compound associated with the production of the compound of claim 1.(f)Claim 7 is an “omnibus” claim. I note that only claims 1 to 4 and 7 are in issue in this proceeding.WITNESSES Eli Lilly relied on the following witnesses: (a)Dr Alan Duncan Robertson, who swore affidavits dated 16 December 2010, 24 June and 12 September 2011. Dr Robertson was cross-examined. Dr Robertson holds a Bachelor of Science (Hons) Degree (1978) and a PhD in synthetic organic chemistry (1981) from the University of Glasgow. Dr Robertson completed a post-doctoral fellowship with the Science and Engineering Research Council at the University of Sussex between 1981 and 1984. He then worked for Wellcome Foundation Ltd where, as a Senior Research Scientist, he worked on a migraine drug marketed as Zomig. In 1992 Dr Robertson migrated to Australia to work for FH Faulding and Company Limited where he managed the development of generic injectable drugs. This role involved reading patents and working the inventions described. (b)Professor David Earl Nichols, who swore affidavits dated 17 December 2010 and 24 June 2011. Professor Nichols was cross-examined. Professor Nichols received a Bachelor’s Degree in Chemistry in 1969 from the University of Cincinnati, and a PhD in Medicinal Chemistry from the University of Iowa in 1973. He completed two years of post-doctoral work there and then moved to Purdue University, where he is currently the Robert C and Charlotte P Anderson Distinguished Chair in Pharmacology. At the priority date, Professor Nichols was a Professor of Pharmacology and Medicinal Chemistry at Purdue University. He has conducted research into drugs that modify consciousness and dopamine receptors, and has particular expertise in the study of small molecules affecting the CNS.(c)Dr Benventuto Capuano, who affirmed an affidavit dated 1 July 2011. Dr Capuano was cross-examined. At the time of swearing his affidavit, Dr Capuano was a Senior Lecturer at the Faculty of Pharmacy & Pharmaceutical Sciences, Monash University. He completed a Bachelor of Applied Science (Applied Chemistry) Degree in 1987, followed by a Master of Pharmacy (1991) and a PhD with the Department of Medicinal Chemistry at Monash University (2001). At the priority date, Dr Capuano was a Masters student and Assistant Lecturer at the Victorian College of Pharmacy. Dr Capuano’s PhD was entitled “The Design, Synthesis and Pharmacological Evaluation of Clozapine Analogues for the Treatment of Schizophrenia”. This examined the differences between “typical” and “atypical” antipsychotic drugs, the available antipsychotic drugs before the priority date and their structural features. Dr Capuano’s PhD included a discussion on key textbooks in the area. (d)Dr Ian Alexander Pullar, who affirmed an affidavit dated 28 July 2011, which largely related to a witness statement that he gave in proceedings regarding the United Kingdom equivalent of the Patent. Dr Pullar was cross-examined. Dr Pullar, a neuropsychopharmacologist, received a Bachelor of Science Degree in 1966 and completed a PhD in Neuroscience in 1971. He was an employee of Eli Lilly from June 1975 until his retirement on 31 January 2005. From 1975 to 1987, Dr Pullar was Head of the CNS Pharmacology group at an Eli Lilly research facility, Erl Wood, in Surrey, United Kingdom. After 1987, he continued as a Senior Research Scientist within Eli Lilly’s Global CNS Pharmacology group. The Pharmacology group was responsible for the research of drugs for the treatment of schizophrenia and depression. (e)Professor Gordon Frederick Stuart Johnson, who swore an affidavit dated 17 May 2011. Professor Johnson was cross-examined. At the time of swearing his affidavit, Professor Johnson was an Emeritus Professor of Psychological Medicine at the University of Sydney. Professor Johnson completed a Bachelor of Medicine Degree and Bachelor of Surgery Degree in 1959. From 1963 to 1964, Professor Johnson trained in psychological medicine in Sussex, UK, and received a Diploma of Psychological Medicine from the Royal College of Physicians & Surgeons UK. Between 1969 and 1970, Professor Johnson was a co-investigator in clinical trials relating to drugs used to treat schizophrenia and bipolar disorder. From 1970 to 1971, he was actively involved in clinical research with new potential psychotropic compounds (drugs for treating mental illnesses) at Schering and Ciba Pharmaceuticals. Professor Johnson has published over 100 articles, reviews, and chapters in books.(f)Professor Guy Manning Goodwin, who swore affidavits dated 4 July 2011 and 18 October 2011. Professor Goodwin was not cross-examined. At the time of swearing his first affidavit, Professor Goodwin was the Head of the Department of Psychiatry and WA Handley Professor of Psychiatry at Merton College, University of Oxford. He was, and has been since 1980, a practising psychiatrist. Professor Goodwin has authored or co-authored over 300 scientific papers, review articles and technical publications in the areas of neuroscience, psychiatry and disorders and function of the CNS. Of these, 35 were co-authored with Australian colleagues. (g)Dr Jeffery Allen Engelhardt, who swore an affidavit dated 24 June 2011. Dr Engelhardt was cross-examined. At the time of swearing his affidavit, Dr Engelhardt was a President and Senior Pathologist of Experimental Pathology Laboratories Incorporated. Dr Engelhardt was employed by Eli Lilly and Company Ltd from 1988 to February 2004 as a veterinary pathologist. His affidavit largely concerned his involvement in animal toxicity studies, conducted in relation to the development of olanzapine, in particular, the dog study D07290 (Lilly Dog Study) conducted by Eli Lilly. (h)Professor John Emery Bauer, who affirmed an affidavit dated 29 June 2011. Professor Bauer was not cross-examined. His affidavit largely concerned the Lilly Dog Study and comparative dog toxicology studies. Professor Bauer was not involved in the Lilly Dog Study. Professor Bauer was, at the time of affirming his affidavit, a Professor at Texas A&M University and a Director of the Comparative Nutrition Research Laboratory at the College of Veterinary Medicine at the same institution. Professor Bauer conducted research on animal nutrition and metabolism, particularly focusing on cholesterol, lipoprotein and serum lipid metabolism in companion animals such as dogs.(i)Professor Ronald Thisted, who swore an affidavit dated 28 June 2011. Professor Thisted was not cross-examined. Professor Thisted was, at the time of swearing his affidavit, the Chairman of the Department of Health Studies at the University of Chicago, as well as a Professor of the Departments of Statistics, Health Studies, Anesthesia and Critical Care and the Undergraduate College at the University of Chicago. He was also a Professor of the Committee on Clinical Pharmacology and Pharmacogenomics. Professor Thisted obtained a PhD in statistics from Stanford University in 1977, and has published a book on statistical computation and over 100 original articles in peer-reviewed journals (including medical journals). He has also published peer-reviewed articles in statistics journals. Professor Thisted’s evidence largely concerned the interpretation and analysis of the Lilly Dog Study and comparative dog toxicology studies. (j)Dr Karl Arthur Traul, who affirmed an affidavit dated 24 June 2011. Dr Traul was not cross-examined. At the time of affirming his affidavit, Dr Traul was the President of K A Traul Pharmaceutical Consulting. Dr Traul obtained a Bachelor’s Degree in Biology in 1963 from the University of Akron, Ohio, a Master of Science in 1965 and later a PhD from Ohio State University in 1969. Between 1969 and 1980 he worked in cancer research and drug safety for Pfizer Pharmaceuticals, ultimately as Laboratory Head and Project Leader. Dr Traul then worked in the area of toxicology for various companies, including Exxon Corporation and American Cyanamid. From 1995 he has worked as a consultant in toxicology and regulatory affairs. Dr Traul largely gave evidence on the Lilly Dog Study and comparative dog toxicology studies.(k)Mr Steven Michael Harrill, who affirmed an affidavit dated 19 August 2011. Dr Harrill was cross-examined. Dr Harrill was, at the time of affirming his affidavit, the Global Brand Director – Neuroscience, of Eli Lilly and Company (US). Mr Harrill has a Bachelor’s Degree in Chemistry and Masters of Business Administration. Mr Harrill has worked for Eli Lilly and Company (US) since July 1985 in various positions. Mr Harrill largely gave evidence on the marketing and sales of various Eli Lilly products.(l)Ms Shihui Yuan, who affirmed an affidavit dated 3 August 2011. Ms Yuan was not cross-examined. Ms Yuan is the Marketing Director of the Bio-medicines business unit of the second applicant, Eli Lilly Australia, and has been so since May 2011. Ms Yuan has an American Language and Literature Degree. After graduating, Ms Yuan worked for Shanghai Loudon Far East, which was a market research firm specialising in the pharmaceutical industry. Since 2001 Ms Yuan has held various marketing roles at Eli Lilly. In her various roles, she has had considerable responsibility for the marketing of Zyprexa products, which contain olanzapine as their active ingredients. Ms Yuan largely gave evidence on the sales of Zyprexa products, and the market share enjoyed by Eli Lilly for these products.(m)Dr Andreas von Falck, who swore an affidavit dated 1 August 2011. Dr von Falck was not cross-examined. Dr von Falck is a partner at the law firm Hogan Lovells International LLP, in the Düsseldorf office. Dr von Falck holds a PhD in International Civil Procedural Law from Freiburg University. Since the European Autumn of 2006, Dr von Falck has represented Eli Lilly in the German proceedings relating to European Patent EP 0454436, the corresponding patent to the Australian Patent in suit. Dr von Falck gave evidence as to steps he undertook to locate a Professor Mager. Professor Mager was co-author of an article known as the “Schauzu Article” (or simply “Schauzu”) in this proceeding.(n)Ms Miriam Gundt, who affirmed an affidavit dated 1 August 2011. Ms Gundt was not cross-examined. Ms Gundt was a colleague (Senior Associate) of Dr von Falck at Hogan Lovells International LLP. Ms Gundt gave similar evidence to that of Dr von Falck.